BioLife Solutions Inc (NASDAQ:BLFS) Given Consensus Recommendation of “Buy” by Brokerages

Shares of BioLife Solutions Inc (NASDAQ:BLFS) have been given an average rating of “Buy” by the nine analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $18.40.

A number of research firms have issued reports on BLFS. BidaskClub raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a report on Thursday. ValuEngine upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Monday, July 22nd. HC Wainwright began coverage on shares of BioLife Solutions in a report on Monday, July 22nd. They issued a “buy” rating and a $23.00 price objective for the company. Zacks Investment Research lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Finally, Maxim Group set a $24.00 price objective on shares of BioLife Solutions and gave the stock a “buy” rating in a report on Wednesday, May 22nd.

BLFS stock traded down $1.55 on Friday, reaching $17.00. The company’s stock had a trading volume of 485,949 shares, compared to its average volume of 174,075. BioLife Solutions has a 52 week low of $9.15 and a 52 week high of $26.35. The company has a market capitalization of $330.88 million, a P/E ratio of 121.57 and a beta of 1.37. The business has a fifty day simple moving average of $17.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.50 and a quick ratio of 12.99.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $6.59 million. BioLife Solutions had a return on equity of 10.32% and a net margin of 17.01%. Research analysts anticipate that BioLife Solutions will post 0.13 earnings per share for the current fiscal year.

In other news, major shareholder Walter Villiger sold 39,883 shares of the company’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $19.18, for a total value of $764,955.94. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP James Mathers sold 2,500 shares of the company’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $17.94, for a total transaction of $44,850.00. Following the completion of the sale, the vice president now directly owns 19,884 shares in the company, valued at $356,718.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 267,878 shares of company stock valued at $4,775,862. Company insiders own 27.00% of the company’s stock.

Several large investors have recently added to or reduced their stakes in BLFS. Russell Investments Group Ltd. lifted its position in BioLife Solutions by 230.8% in the second quarter. Russell Investments Group Ltd. now owns 299,240 shares of the medical equipment provider’s stock worth $5,067,000 after buying an additional 208,786 shares during the last quarter. FMR LLC acquired a new stake in BioLife Solutions during the first quarter valued at approximately $2,684,000. Roubaix Capital LLC raised its stake in BioLife Solutions by 165.9% during the second quarter. Roubaix Capital LLC now owns 120,313 shares of the medical equipment provider’s stock valued at $2,039,000 after buying an additional 75,068 shares in the last quarter. Quantum Capital Management acquired a new stake in BioLife Solutions during the first quarter valued at approximately $852,000. Finally, Laurion Capital Management LP grew its holdings in shares of BioLife Solutions by 74.0% during the first quarter. Laurion Capital Management LP now owns 84,944 shares of the medical equipment provider’s stock valued at $1,520,000 after purchasing an additional 36,136 shares during the last quarter. 45.92% of the stock is currently owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Article: Dow Jones Industrial Average (DJIA)

Analyst Recommendations for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.